by Richard Daverman, PhD
December 20, 2012 -- Guangzhou Techpool Bio-Pharma in-licensed the China rights to Bondronat, an oncology drug from Roche. Bondronat is a treatment for metastatic bone cancer. It treats pain along with fractures, spine compression and hypercalcaemia. Techpool believes the contract, which runs for five years, will not yield a profit during the first two years, during which time the company will focus primarily on education. More details....
Stock Symbol: (VS: ROG)
